Peripheral blood levels of matrix and inflammatory mediators are elevated in Tunisian patients with acute coronary syndromes

Clinical Laboratory

Volumn 59, Issue 1-2, 2013, Pages 169-175

  Zayani, Yosra ^a   Allal Elasmi, Monia ^a   Jacob, Marie Paule ^b   Zidi, Wiem ^a   Zaroui, Amira ^a   Feki, Moncef ^a   Mourali, Sami ^a   Mechmech, Rachid ^a   Kaabachi, Naziha ^a  

^a LA RABTA HOSPITAL   (Tunisia)

^b INSERM   (France)

Author keywords

Acute coronary syndrome; C reactive protein; Fibrinogen; Matrix metalloproteinases; Tissue inhibitors matrix metalloproteinases; White blood cells number

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; CARDIAC PATIENT; CASE CONTROL STUDY; CONTROLLED STUDY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PROTEIN BLOOD LEVEL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STABLE ANGINA PECTORIS; TUNISIA; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; AGED; C-REACTIVE PROTEIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOGEN; HUMANS; INFLAMMATION MEDIATORS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUNISIA;

EID: 84874595859     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: 10.7754/Clin.Lab.2012.120223     Document Type: Article

References (42)

1. Dabek J, Kulach A, Gasior Z. The role of matrix metalloproteinases in acute coronary syndromes. Eur J Intern Med 2007;18:463-6. (Pubitemid 47379537)
2. Manginas A, Bei E, Chaidaroglou A, et al. Peripheral Levels of Matrix Metalloproteinase-9, Interleukin-6, and C-Reactive Protein Are Elevated in Patients with Acute Coronary Syndromes: Correlations with Serum Troponin I Clin Cardiol 2005;28:182-6. (Pubitemid 40471698)
3. Ramasamy I. Biochemical markers in acute coronary syndrome. Clinica Chimica Acta 2011;412:1279-96.
4. Shah PK, Falk E, Badimon JJ, et al. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Circulation 1995;92:1565-9.
5. Kaartinen M, van der Wal AC, van der Loos CM, et al. Mast cell infiltration in acute coronary syndromes: implications for plaque rupture. J Am Coll Cardiol 1998;32:606-12. (Pubitemid 28445520)
6. Inokubo Y, Hanada H, Ishizaka H, Fukushi T, Kamada T, Okumura K. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J 2001;141:211-7. (Pubitemid 32128725)
7. Papazafiropoulou A, Tentolouris N. Matrix metalloproteinases and cardiovascular diseases. Hippkratia 2009;13:76-82.
8. Benjamin MM, Khalil RA. Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease. EXS 2012;103:209-79.
9. Eckart RE, Uyehara CF, Shry EA, Furgerson JL, Krasuski RA. Matrix metalloproteinases in patients with myocardial infarction and percutaneous revascularization. J Interv Cardiol 2004;17:27-31. (Pubitemid 38326510)
10. Kai H, Ikeda H, Yasukawa H, et al. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 1998;32:368-72. (Pubitemid 28396484)
11. Blankenberg S, Rupprecht HJ, Poirier O et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003;107:1579-85. (Pubitemid 36397324)
12. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999;340:115-26.
13. Biasucci LM. CDC/AHA workshop on markers of inflammation and cardiovascular disease application to clinical and public health practice clinical use of inflammatory markers in patients with cardiovascular diseases. Circulation 2004;110:560-7.
14. Tziakas DN, Chahkias GK, Kaski JC, et al. Inflammatory and anti-inflammatory variable clusters and risk prediction in acute coronary syndrome patients: A factor analysis approach. Atherosclerosis 2007;193:196-203. (Pubitemid 46776700)
15. Jacob MP. Extracellular matrix remodeling and matrix metalloproteinases in the vascular wall during aging and in pathological conditions. Biomed Pharmacother 2003;57:195-202. (Pubitemid 36897685)
16. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994;94:2493-503. (Pubitemid 24379627)
17. Pasterkamp G, Schoneveld AH, Hijnen DJ, et al. Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteases 1, 2, and 9 in the human coronary artery. Atherosclerosis 2000;150:245-53. (Pubitemid 30336536)
18. Opdenakker G, Van den Steen PE, Dubois B, et al. Gelatinase B functions as regulator and effector in leukocyte biology. J Leukoc Biol 2001;69:851-9. (Pubitemid 32577883)
19. Zeng B, Prasan A, Fung KC, et al. Elevated circulating levels of matrix metalloproteinase-9 and -2 in patients with symptomatic coronary artery disease. Intern Med J 2005;35:331-5. (Pubitemid 40826856)
20. Ferroni P, Basili S, Martini F, et al. Serum metalloproteinase 9 levels in patients with coronary artery disease: a novel marker of inflammation. J Investig Med 2003;51:295-300. (Pubitemid 37210891)
21. Blankenberg S, Rupprecht HJ, Poirier O, et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003;107:1579-85. (Pubitemid 36397324)
22. Brown DL, Hibbs MS, Kearney M, Loushin C, Isner JM. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. Circulation 1995;91:2125-31.
23. Lei Wang, Yi-tong Ma, Xiang Xie, et al. Association of MMP-9 gene polymorphisms with acute coronary syndrome in the Uygur population of China. World J Emerg 2011;2:104-10.
24. Nanni S, Melandri G, Hanemaaijer R, et al. Matrix metalloproteinases in premature coronary atherosclerosis: influence of inhibitors, inflammation, and genetic polymorphisms. Transl Res 2007;149:137-44. (Pubitemid 46275571)
25. Bigg HF, Rowan AD, Barker MD, Cawston TE. Activity of matrix metalloproteinase-9 against native collagen types I and III. FEBS J 2007;274:1246-55.
26. Giansante C, Fiotti N, Di Chiara A, et al. In-hospital outcome of patients with acute coronary syndrome: relationship with inflammation and remodeling markers. J Cardiovasc Med 2007; 8:602-7. (Pubitemid 47222174)
27. Linlin Wang, Tiebing Zhu, Yong Li. Relationship between matrix metalloproteinase-9 polymorphism and acute coronary syndrome. Journal of Nanjing Medical University 2007;21:147-50.
28. Derosa G, D'Angelo A, Scalise F, et al. Comparison between metalloproteinases-2 and -9 in healthy subjects, diabetics, and subjects with acute coronary syndrome. Heart Vessels 2007;22:361-70. (Pubitemid 350201431)
29. Tziakas DN, Chalikias GK, Parissis JT, et al. Serum profiles of matrix metalloproteinases and their tissue inhibitor in patients with acute coronary syndromes. The effects of short-term atorvastatin administration. Int J Cardiol 2004;94:269-77. (Pubitemid 38490672)
30. Hong Jin, Geng Peng, Dongming Wang, Chuanzhe Yue, Yuguang Li. The serum levels of MMP-9, sICAM-1, CRP and WBC increased in patients with acute coronary syndrome. Journal of Nanjing Medical University 2007;21:222-6.
31. Rossignol P, Cambillau M, Bissery A, et al. Influence of blood sampling procedure on plasma concentrations of matrix metalloproteinases and their tissue inhibitors. Clin Exp Pharmacol Physiol 2008;35:464-9. (Pubitemid 351326780)
32. Brew K, Nagase H. The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim Biophys Acta 2010;1803:55-71.
33. Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Circ Res 2001;89:763-71. (Pubitemid 34633846)
34. Blake GJ, Ridker PM. Novel clinical markers of vascular wall inflammation. Circ Res 2001;89:763-71. (Pubitemid 34633846)
35. Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 2001;103:1194-7. (Pubitemid 32221339)
36. Blake GJ, Ridker PM. C-Reactive Protein and Other Inflammatory Risk Markers in Acute Coronary Syndromes. J Am Coll Cardiol 2003;41:37-42.
37. Zairis MN, Adamopoulou EN, Manousakis SJ, et al. The impact of hs C-reactive protein and other inflammatory biomarkers on long-term cardiovascular mortality in patients with acute coronary syndromes. Atheroscleros 2007;194:397-402. (Pubitemid 47513066)
38. Yasojima K, Schwab C, McGeer EG, McGeer PL. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol 2001;158:1039-51. (Pubitemid 32221796)
39. Gil M, Zarebiński M, Adamus J. Plasma fibrinogen and troponin I in acute coronary syndrome and stable angina. Int J Cardio. 2002;83:43-6. (Pubitemid 34311877)
40. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001;104:365-72. (Pubitemid 32666962)
41. Takeda Y, Suzuki S, Fukutomi T, et al. Elevated white blood cell count as a risk factor of coronary artery disease: inconsistency between forms of the disease. Jpn Heart J 2003;44:201-11. (Pubitemid 41519019)
42. Bossé M, Chakir J, Rouabhia M, Boulet LP, Audette M, Laviolette M. Serum matrix metalloproteinase-9: tissue inhibitor of metalloproteinase-1 ratio correlates with steroid responsiveness in moderate to severe asthma. Am J Respir Crit Care Med 1999;195:596-602. (Pubitemid 29084886)